Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

SALT LAKE CITY, UT USA (Press Release) - January 23, 2014 - Myriad Genetics, Inc. today announced that results from four studies in prostate cancer with Prolaris® and one study in renal cancer will be presented at the 2014 ASCO Genitourinary Cancers Symposium, which will be held Jan. 30-Feb. 1, 2014 in San Francisco, Calif.

Prolaris is a prognostic test that accurately predicts cancer-specific death and metastases based on an analysis of 46 cell cycle progression genes. The Prolaris score is a stronger predictor of prostate cancer death and recurrence than clinical parameters such as Gleason score and PSA and has been validated in 11 clinical studies with more than 5,000 patients. The Company also will present data from a study with an investigational prognostic test in development for renal cell carcinoma.

 

2014 ASCO GU – POSTER PRESENTATIONS


Title: Prolaris CCP score stratifies risk for prostate cancer patients at biopsy: initial commercial results.
Presenter: David Crawford
Date: Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)

Title: Cell cycle progression score significantly modifies treatment decisions in prostate cancer: Results of an ongoing registry trial.
Presenter: Ashok Kar
Date: Friday, Jan. 31, 12:00 to 1:30 p.m. and 5:45 to 7:15 p.m. PST (Poster Session B)

Title: Prognostic utility of the cell cycle progression score generated from needle biopsy in men treated with prostatectomy.
Presenter: Jay Bishoff
Date: Thursday, Jan. 30, 11:30 a.m. to 1:00 p.m. and 5:15 to 6:45 p.m. PST (Poster Session A)

Title: Cell cycle progression score to predict metastatic progression of clear cell renal carcinoma after resection.
Presenter: Erik Askeland
Date: Saturday, Feb. 1, 6:45 to 7:55 a.m. and 11:30 a.m. to 12:30 p.m. PST (Poster Session C)

About Prolaris®

Prolaris is a novel prognostic test developed by Myriad Genetics that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of multiple genes related to the progression of tumor cell division. Prolaris can identify low-risk patients who may be candidates for surveillance as well as patients who may be potentially at higher risk and would benefit from closer monitoring or additional therapy. Prolaris has been proven to predict prostate cancer-specific disease progression in five published clinical trials. For more information visit: www.prolaris.com and www.myriad.com/understanding-prostate-cancer/.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

###

Myriad Genetics

[ PRESS RELEASE ]

 

 

Calendar
Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor